Sangjun Yoo1, Hwancheol Son1, Sohee Oh2, Juhyun Park1, Sung Yong Cho1, Min Chul Cho1, Hyeon Jeong3. 1. Department of Urology, Seoul National University College of Medicine, Boramae Medical Center, Sindaebang 2(i)-Dong, Dongjak-gu, Seoul, 07061, Korea. 2. Department of Biostatistics, Seoul National University Boramae Medical Center, Seoul, Korea. 3. Department of Urology, Seoul National University College of Medicine, Boramae Medical Center, Sindaebang 2(i)-Dong, Dongjak-gu, Seoul, 07061, Korea. drjeongh@gmail.com.
Abstract
PURPOSE: To develop a novel biopsy-related parameter, named overlapping line, defined as the line between the adjacent positive cores on 12-core trans-rectal ultrasound-guided prostate biopsy, and evaluated the value of overlapping line for predicting tumor volume in the final pathologic examination. METHODS: Among patients with prostate cancer who underwent radical prostatectomy at Boramae Medical Center, 470 patients who underwent standard 12-core trans-rectal ultrasound-guided prostate biopsy were selected for the analysis. The number of overlapping line was determined in each patient, and its effects on tumor volume were evaluated after adjusting for other variables. RESULTS: Median prostate specific antigen level was 9.1 ng/mL, and the maximum % cancer in positive cores was 42.8%. Median numbers of positive cores and overlapping lines were three and two, respectively. The pathologic stage was T2 or less, T3a, and T3b or greater in 297 (63.5%), 104 (22.2%), and 67 patients (14.3%), respectively. Median tumor volume in prostatectomy specimen was 3.4 mL. In multivariable analysis, the number of overlapping lines (B 0.750, p < 0.001) was a significant predictor for tumor volume, in addition to prostate specific antigen level and maximum % cancer in positive cores. In addition, the model with overlapping line showed superior accuracy compared to the model with positive core based adjusted r 2 (0.467 vs. 0.456). CONCLUSIONS: The number of overlapping lines, a novel prostate biopsy-related variable, is thought to be a more reliable predictor for tumor volume compared to the number of positive cores and could be easily applied to routine daily practice.
PURPOSE: To develop a novel biopsy-related parameter, named overlapping line, defined as the line between the adjacent positive cores on 12-core trans-rectal ultrasound-guided prostate biopsy, and evaluated the value of overlapping line for predicting tumor volume in the final pathologic examination. METHODS: Among patients with prostate cancer who underwent radical prostatectomy at Boramae Medical Center, 470 patients who underwent standard 12-core trans-rectal ultrasound-guided prostate biopsy were selected for the analysis. The number of overlapping line was determined in each patient, and its effects on tumor volume were evaluated after adjusting for other variables. RESULTS: Median prostate specific antigen level was 9.1 ng/mL, and the maximum % cancer in positive cores was 42.8%. Median numbers of positive cores and overlapping lines were three and two, respectively. The pathologic stage was T2 or less, T3a, and T3b or greater in 297 (63.5%), 104 (22.2%), and 67 patients (14.3%), respectively. Median tumor volume in prostatectomy specimen was 3.4 mL. In multivariable analysis, the number of overlapping lines (B 0.750, p < 0.001) was a significant predictor for tumor volume, in addition to prostate specific antigen level and maximum % cancer in positive cores. In addition, the model with overlapping line showed superior accuracy compared to the model with positive core based adjusted r 2 (0.467 vs. 0.456). CONCLUSIONS: The number of overlapping lines, a novel prostate biopsy-related variable, is thought to be a more reliable predictor for tumor volume compared to the number of positive cores and could be easily applied to routine daily practice.
Authors: Ryan K Berglund; Timothy A Masterson; Kinjal C Vora; Scott E Eggener; James A Eastham; Bertrand D Guillonneau Journal: J Urol Date: 2008-09-17 Impact factor: 7.450
Authors: Erik Rud; Dagmar Klotz; Kristin Rennesund; Eduard Baco; Viktor Berge; Diep Lien; Aud Svindland; Eskild Lundeby; Rolf E Berg; Lars M Eri; Heidi B Eggesbø Journal: BJU Int Date: 2014-12 Impact factor: 5.588
Authors: F Cornud; Gaby Khoury; Naim Bouazza; Frederic Beuvon; Michael Peyromaure; Thierry Flam; Marc Zerbib; Paul Legmann; Nicolas B Delongchamps Journal: J Urol Date: 2013-12-12 Impact factor: 7.450
Authors: Marc A Dall'Era; Peter C Albertsen; Christopher Bangma; Peter R Carroll; H Ballentine Carter; Matthew R Cooperberg; Stephen J Freedland; Laurence H Klotz; Christopher Parker; Mark S Soloway Journal: Eur Urol Date: 2012-06-07 Impact factor: 20.096
Authors: J J Knoedler; R J Karnes; R H Thompson; L J Rangel; E J Bergstralh; S A Boorjian Journal: Prostate Cancer Prostatic Dis Date: 2014-01-28 Impact factor: 5.554
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Jelle O Barentsz; Jeffrey C Weinreb; Sadhna Verma; Harriet C Thoeny; Clare M Tempany; Faina Shtern; Anwar R Padhani; Daniel Margolis; Katarzyna J Macura; Masoom A Haider; Francois Cornud; Peter L Choyke Journal: Eur Urol Date: 2015-09-08 Impact factor: 20.096
Authors: Christian P Meyer; Jens Hansen; Katharina Boehm; Derya Tilki; Firas Abdollah; Quoc-Dien Trinh; Margit Fisch; Guido Sauter; Markus Graefen; Hartwig Huland; Felix K H Chun; Sascha A Ahyai Journal: World J Urol Date: 2016-06-03 Impact factor: 4.226